Pulmonary cavitary disease due to Mycobacterium xenopi

Yousri Ben Abdallah; Nabil Belfeki; Timothée Klopfenstein; Souheil Zayet

doi:10.1016/j.imj.2021.11.001

Pulmonary cavitary disease due to Mycobacterium xenopi

Infect Med (Beijing). 2022 Jan 1;1(1):63-66. doi: 10.1016/j.imj.2021.11.001. eCollection 2022 Mar.

Authors

Yousri Ben Abdallah¹, Nabil Belfeki², Timothée Klopfenstein³, Souheil Zayet³

Affiliations

¹ Pneumology Department, Hôpital Nord Franche-Comté (HNFC), Belfort, France.
² Internal Medicine Department, Groupe Hospitalier Sud Ile de France, Melun, France.
³ Infectious Diseases Department, Hôpital Nord Franche-Comté (HNFC), Belfort, France.

Abstract

Non-tuberculous mycobacteria are a significant cause of pulmonary infections worldwide and can be clinically challenging. Mycobacterium xenopi (M. xenopi) has a low pathogenicity and usually requires immunosuppression or lung diseases. We describe herein a scarce case of pulmonary cavitary disease attributed to M. xenopi in a 57-year-old Caucasian patient with underlying structural lung disease successfully treated with rifampicin, ethambutol, clarithromycin, and amikacin.

Keywords: COPD; Mycobacterium xenopi; Non-tuberculous mycobacteria; Pulmonary cavitary disease.

Publication types

Case Reports